Portfolio Company News

Catalysis: Our Spotlight on Amolyt, Mediar and Violet
December 7, 2023

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
November 28, 2023

Amolyt Pharma Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
November 16, 2023

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis
November 13, 2023

Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
November 8, 2023

Emerging Life Science Company of the Year: Mediar Therapeutics, NEVY, New England Venture Capital Association Unveils Nominees and Academies for the 11th Annual NEVY Awards
November 7, 2023

Making Waves at Rippl: Quarterly CEO Update – November 2023
November 1, 2023

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition
October 25, 2023

Rippl Care named to Top 50 emerging health IT vendors
October 5, 2023

InStride Health, a Specialty Pediatric Anxiety/OCD Outpatient Treatment Provider, Shares Clinically Meaningful Results in First Annual Outcomes Report
October 5, 2023

ROME Expands Leadership Team with the Appointment of Industry Veteran Kyle Kuvalanka as Chief Financial Officer and Chief Business Officer
October 4, 2023

ROME Therapeutics Closes Oversubscribed $72 Million Series B Extension to Support Advancement of Lead Program into Clinical Development for Autoimmune Disease
September 12, 2023

Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline
August 17, 2023

Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
July 24, 2023

Lyndra Therapeutics Announces Leadership Changes, Update on Pivotal Trial Progress
July 17, 2023

Garuda Therapeutics Announces the Appointment of Giorgia Scapin, PhD, as Chief Scientific Officer
July 13, 2023

Amolyt Pharma Announces Initiation of Phase 1 Clinical Trial of Peptide Growth Hormone Receptor Antagonist (GHRA), AZP-3813, for Acromegaly
June 5, 2023

Violet Therapeutics raises $10.6 million in seed funding led by the Dementia Discovery Fund (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and Mass General Brigham Ventures (MGBV)
May 31, 2023

SwanBio Therapeutics Confirms Substantial Burden of Disease of Adrenomyeloneuropathy (AMN) in Both Men and Women
May 10, 2023

Lyndra Therapeutics Doses First Clinical Trial Participant in Pivotal Study of Oral Weekly Risperidone (LYN-005) for Schizophrenia and Schizoaffective Disorder
May 9, 2023

Amolyt Pharma Announces Phase 3 Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism
May 2, 2023

Reintroducing Catalysis: Start-up News for the Mass General Brigham Community
April 19, 2023

Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets
April 4, 2023

Mediar Therapeutics Announces $105 Million Financing to Advance Portfolio of First-in-Class Fibrosis Therapies
March 15, 2023

QurAlis Closes $88 Million Series B Financing to Advance Precision Medicines for Neurodegenerative Diseases
March 9, 2023

Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
February 7, 2023

Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group
January 6, 2023

QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
January 5, 2023

Lyndra Therapeutics Announces New Board Members and Chief Technology Officer
January 05, 2023

ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics 
January 03, 2023

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Pancreatic Cancer
December 27, 2022

SwanBio Therapeutics Initiates First-in-Human Study of AAV Gene Therapy for Adrenomyeloneuropathy
December 15, 2022

SeQure Dx Emerges from Stealth Mode to Fulfill the Promise of On-Target Gene Editing Therapies
November 16, 2022

ZielBio Receives Orphan Drug Designation for ZB131 for the Treatment of Cholangiocarcinoma
November 15, 2022

Garuda Therapeutics Announces Appointment of David DiGiusto, PhD, as Chief Technology Officer
November 15, 2022

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
October 18, 2022

Amolyt Pharma Announces Positive Safety and Efficacy Results from Second Patient Cohort in its Phase 2a Trial of AZP-3601 for the Treatment of Hypoparathyroidism
October 12, 2022  

Abcuro Initiates Phase 1/2 Trial Evaluating ABC008 in Patients with T Cell Large Granular Lymphocytic Leukemia 
October 4, 2022

Abcuro Appoints Alex Martin as Chief Executive Officer 
October 3, 2022

InStride Health Providing Virtual Pediatric Anxiety/OCD Treatment Launches with Support from McLean Hospital and Leading Healthcare Investors 
October 3, 2022

New Mental Health Company to Revolutionize Mental Health Care Delivery for Seniors 
September 28, 2022

Endpoints News Announces the 11 Most Promising Biotech Startups of 2022 
September 22, 2022

GSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset 
September 22, 2022

Keros Therapeutics Presents Additional Clinical Data from its KER-012 Program 
September 12, 2022

Amolyt Pharma Announces Positive Efficacy and Safety Data from First Cohort of Phase 2a Study 
September 12, 2022

Scorpion Therapeutics named by Fierce Biotech as one of its “Fierce 15” Biotech Companies of 2022 
September 12, 2022

Photys Therapeutics Debuts with $75 Million Series A Funding
September 8, 2022

Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer
September 7, 2022

Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease 
July 20, 2022

Lyndra Therapeutics Doses First Clinical Trial Participant in Study of Oral Biweekly Ivermectin 
June 9, 2022

Amolyt Pharma Announces Positive Results from First Patient Cohort of Phase 2a Trial of AZP-3601 
June 1, 2022

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies 
May 18, 2022

Amolyt Pharma Announces US IND Clearance for the Ongoing Clinical Trial of AZP-3601 
March 17, 2022

Garuda Therapeutics Announces Appointment of James Desiderio as Chief Regulatory Officer 
March 15, 2022

Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, MD, to Board 
March 8, 2022

Amolyt Pharma Announces European Commission Has Granted Orphan Drug Designation to AZP-3601 
March 1, 2022

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel 
January 13, 2022

Gene therapy player Affinia aims to go public, hoping to raise big money in effort to remake AAVs 
January 5, 2022

Scorpion Therapeutics Receives BioSpace NextGen Bio “Class of 2022” Recognition
January 5, 2022

Garuda thinks it has cracked the code to off-the-shelf stem cell transplants—and investors are betting $72 million to find out
September 23, 2021

Amolyt Pharma Announces $80 Million Series B Financing
September 16, 2021

Simon Sturge Joins Mediar Therapeutics as Executive Chairman
September 15, 2021

ROME Therapeutics Secures $77 Million in Series B Financing
September 14, 2021

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group 
September 8, 2021

Nocion Therapeutics Announces Dosing Underway in Participants with Chronic Cough 
August 31, 2021

Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal 
August 4, 2021

Gene Editing Analysis Firm SeQure Dx Closes $17.5M Series A Funding Round
August 3, 2021

Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications
July 19, 2021

Lyndra Therapeutics Completes $60.5 Million Series C Financing 
June 24, 2021

Verve Therapeutics Announces Pricing of Initial Public Offering 
June 16, 2021

Gene editing biotech Verve indicates a swift swerve onto Wall Street, asking for $100M IPO 
June 1, 2021

Amolyt Pharma to Present New Phase 1 Data on AZP-3601, its Parathyroid Hormone Analog for Hypoparathyroidism, and Preclinical Data on AZP-3404 at Upcoming Scientific Conferences
May 18, 2021

Looking to reinvent those troubled AAVs you've been reading about, investors back a $110M reboot  
April 30, 2021

Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment 
April 18, 2021

Its Parathyroid Hormone Analog for Hypoparathyroidism, at the Endocrine Society’s Virtual Annual Meeting (ENDO 2021) 
March 22, 2021

Mediar Therapeutics Adds New Investors As It Advances Anti-Fibrotic Treatments
March 17, 2021

Affinia Therapeutics Announces Addition of Gene Therapy
February 17, 2021

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline
January 19, 2021

Scorpion Therapeutics strikes major $162M funding round for 'precision oncology 2.0'
January 7, 2021

Abcuro will take an anti-KLRG1 antibody into the clinic with new funding, and has big plans for another 
January 7, 2021

Amolyt Pharma Receives Orphan Drug Designation for AZP-3601 for the Potential Treatment of Hypoparathyroidism
January 6, 2021

ZielBio Appoints Dieter Weinand Executive Chair 
December 9, 2020 

Amolyt Pharma Announces Research Collaboration with PeptiDream 
December 8, 2020

Keros Therapeutics Announces Pricing of Public Offering of Common Stock 
November 12, 2020

Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' 
October 26, 2020

Amolyt Pharma Doses First Subject in Phase 1 Clinical Trial of Parathyroid Hormone Analog, AZP-3601  
October 14, 2020

Walden Biosciences Launches to Transform the Treatment of Kidney Disease28
October 6, 2020

BIAL Goes Global w/ New US Research Center and Acquisition of Promising Parkinson's Disease Program 
October 1, 2020

Nocion Therapeutics Advances to Clinical Stage and Expands Leadership
September 1, 2020

Verve Therapeutics Raises $63M to Advance Gene-Editing Therapies for Heart Diseases 
June 11, 2020

Lyndra Therapeutics Achieves Critical Milestones Despite COVID-19 Headwinds 
June 11, 2020

3 months after its B round, Akouos files an IPO to the tune of $100M 
June 8, 2020

Alizé Pharma 3 Announces Rebranding to Amolyt Pharma, Reflecting a Strategic Focus on Building and Advancing a Portfolio of Therapeutic Peptides for Rare Endocrine and Metabolic Diseases 
June 2, 2020

ROME Therapeutics Launches to Develop Novel Therapies for Cancer and Autoimmune Diseases by Harnessi 
April 27, 2020

Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration
April 27, 2020

SwanBio Therapeutics Announces Series A Expansion to Fund its Lead Program and Grow Pipeline in Gene 
April 23, 2020

Keros Therapeutics Raises $96M in Upsized IPO to Fuel Clinical Tests 
April 8, 2020

Akouos Closes $105 Million Series B Financing
March 3, 2020